JW Pharma is expanding AI technology from new drugs to raw drug research fields to increase R&D efficiency. JW Pharma announced on the 30th that it recently signed a business agreement with Merck Life Science in Germany to research and develop raw materials for new drugs using AI.

Merck offers its AI software Synthia to JW Pharma. Synthia is a program that quickly analyzes and provides the synthesis route of raw drugs in the new drug development stage. Merck's Custom Synthesis Lab's know-how in synthesizing new materials is also consulted with JW Pharma. JW Pharma's raw material research center plans to actively utilize Synthia for research on the synthesis of its new drug candidates. It is expected to